TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Russell Investments Group Ltd.

Russell Investments Group Ltd. increased its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 323.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,706 shares of the biopharmaceutical company's stock after buying an additional 26,506 shares during the period. Russell Investments Group Ltd.'s holdings in TG Therapeutics were worth $1,045,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Blue Trust Inc. lifted its holdings in TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 371 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp increased its stake in TG Therapeutics by 460.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after buying an additional 1,737 shares in the last quarter. Synergy Asset Management LLC purchased a new position in shares of TG Therapeutics in the fourth quarter valued at approximately $75,000. Finally, GAMMA Investing LLC boosted its stake in shares of TG Therapeutics by 562.4% in the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock worth $77,000 after acquiring an additional 2,171 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Trading Up 1.8 %

Shares of NASDAQ:TGTX traded up $0.73 during midday trading on Friday, reaching $41.03. 922,877 shares of the company's stock were exchanged, compared to its average volume of 3,086,248. The stock has a market cap of $6.51 billion, a price-to-earnings ratio of -410.84 and a beta of 2.14. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $43.32. The firm's 50 day simple moving average is $36.98 and its two-hundred day simple moving average is $32.31. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million during the quarter, compared to analysts' expectations of $100.67 million. As a group, sell-side analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on TGTX. HC Wainwright reaffirmed a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.